Changsu Han,, Mhs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4321350/publications.pdf

Version: 2024-02-01

246 papers 7,888 citations

46918 47 h-index 74 g-index

248 all docs

248 docs citations

248 times ranked

10452 citing authors

#	Article	IF	Citations
1	Validation of the Patient Health Questionnaire-9 Korean version in the elderly population: the Ansan Geriatric study. Comprehensive Psychiatry, 2008, 49, 218-223.	1.5	344
2	A Double-Blind Trial of Risperidone and Haloperidol for the Treatment of Delirium. Psychosomatics, 2004, 45, 297-301.	2.5	249
3	Low plasma BDNF is associated with suicidal behavior in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 78-85.	2.5	248
4	An adaptation of the Korean mini-mental state examination (K-MMSE) in elderly Koreans: Demographic influence and population-based norms (the AGE study). Archives of Gerontology and Geriatrics, 2008, 47, 302-310.	1.4	231
5	The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Molecular Psychiatry, 2002, 7, 1107-1114.	4.1	203
6	Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review. Chonnam Medical Journal, 2018, 54, 101.	0.5	181
7	Th1, Th2 and Th3 cytokine alteration in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 1129-1134.	2.5	164
8	Comparison of the Usefulness of the PHQ-8 and PHQ-9 for Screening for Major Depressive Disorder: Analysis of Psychiatric Outpatient Data. Psychiatry Investigation, 2019, 16, 300-305.	0.7	151
9	Oxidative/nitrosative stress and antidepressants: Targets for novel antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 46, 224-235.	2.5	124
10	Usefulness of Beck Depression Inventory (BDI) in the Korean elderly population. International Journal of Geriatric Psychiatry, 2007, 22, 218-223.	1.3	122
11	Symptom severity and attitudes toward medication: Impacts on adherence in outpatients with schizophrenia. Schizophrenia Research, 2012, 134, 226-231.	1.1	105
12	Association between a G-protein \hat{l}^2 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics Journal, 2004, 4, 29-33.	0.9	103
13	Assessment of the Type D Personality Construct in the Korean Population: A Validation Study of the Korean DS14. Journal of Korean Medical Science, 2011, 26, 116.	1.1	101
14	Depression Is Associated with Sarcopenia, Not Central Obesity, in Elderly Korean Men. Journal of the American Geriatrics Society, 2011, 59, 2062-2068.	1.3	101
15	Prevalence and Associated Factors of Depression in General Population of Korea: Results from the Korea National Health and Nutrition Examination Survey, 2014. Journal of Korean Medical Science, 2017, 32, 1861.	1.1	101
16	Does minocycline have antidepressant effect?. Biomedicine and Pharmacotherapy, 2008, 62, 308-311.	2.5	98
17	Increased plasma nitric oxide level associated with suicide attempt in depressive patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 1091-1096.	2,5	93
18	T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Research, 2004, 129, 267-272.	1.7	90

#	Article	IF	Citations
19	Psychometric Properties of the Patient Health Questionnaire-15 (PHQ-15) for Measuring the Somatic Symptoms of Psychiatric Outpatients. Psychosomatics, 2009, 50, 580-585.	2.5	88
20	A Glu487Lys polymorphism in the gene for mitochondrial aldehyde dehydrogenase 2 is associated with myocardial infarction in elderly Korean men. Clinica Chimica Acta, 2007, 382, 43-47.	0.5	87
21	Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Review of Neurotherapeutics, 2013, 13, 851-870.	1.4	83
22	High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users. Neuroscience Letters, 2005, 388, 112-115.	1.0	82
23	A review of current evidence for acetyl-l-carnitine in the treatment of depression. Journal of Psychiatric Research, 2014, 53, 30-37.	1.5	80
24	Mental Health of Healthcare Workers who Experience Needlestick and Sharps Injuries. Journal of Occupational Health, 2006, 48, 474-479.	1.0	79
25	Pain and Depression: A Neurobiological Perspective of Their Relationship. Psychiatry Investigation, 2015, 12, 1.	0.7	77
26	Increased Plasma Nitric Oxide Metabolites in Suicide Attempters. Neuropsychobiology, 2006, 53, 127-132.	0.9	74
27	Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. Expert Review of Neurotherapeutics, 2007, 7, 1251-1263.	1.4	74
28	Influence of FKBP5 polymorphism and DNA methylation on structural changes of the brain in major depressive disorder. Scientific Reports, 2017, 7, 42621.	1.6	74
29	Usefulness of the 15-item geriatric depression scale (GDS-15) for classifying minor and major depressive disorders among community-dwelling elders. Journal of Affective Disorders, 2019, 259, 370-375.	2.0	70
30	Social capital, socioeconomic status, and depression in community-living elderly. Journal of Psychiatric Research, 2018, 98, 133-140.	1.5	68
31	Social participation and depressive symptoms in community-dwelling older adults: Emotional social support as a mediator. Journal of Psychiatric Research, 2021, 137, 589-596.	1.5	68
32	Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: A pilot study on differential effects of sex hormones on antidepressant effects. Biomedicine and Pharmacotherapy, 2009, 63, 228-235.	2.5	67
33	Association between Norepinephrine Transporter Gene Polymorphism and Major Depression. Neuropsychobiology, 2004, 49, 174-177.	0.9	66
34	Sensitivity of cognitive tests in four cognitive domains in discriminating MDD patients from healthy controls: a meta-analysis. International Psychogeriatrics, 2013, 25, 1543-1557.	0.6	65
35	Morbidity and related factors among elderly people in South Korea: results from the Ansan Geriatric (AGE) cohort study. BMC Public Health, 2007, 7, 10.	1.2	63
36	Region and frequency specific changes of spectral power in Alzheimer's disease and mild cognitive impairment. Clinical Neurophysiology, 2011, 122, 2169-2176.	0.7	63

#	Article	IF	Citations
37	The cutoff values of visceral fat area and waist circumference for identifying subjects at risk for metabolic syndrome in elderly Korean: Ansan Geriatric (AGE) cohort study. BMC Public Health, 2009, 9, 443.	1.2	59
38	Characteristics and clinical correlates of restless legs syndrome in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1078-1083.	2.5	58
39	Plasma Homocysteine Is Associated with the Risk of Mild Cognitive Impairment in an Elderly Korean Population ,. Journal of Nutrition, 2007, 137, 2093-2097.	1.3	58
40	The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry. Contemporary Clinical Trials, 2009, 30, 116-122.	0.8	58
41	Identification of peripheral inflammatory markers between normal control and Alzheimer's disease. BMC Neurology, 2011, 11, 51.	0.8	58
42	Association Between Visceral Obesity and Sarcopenia and Vitamin D Deficiency in Older Koreans: The Ansan Geriatric Study. Journal of the American Geriatrics Society, 2012, 60, 700-706.	1.3	56
43	Safety and Tolerability of Lamotrigine. Clinical Neuropharmacology, 2011, 34, 39-47.	0.2	53
44	Influence of <i>BDNF</i> Variants on Diagnosis and Response to Treatment in Patients with Major Depression, Bipolar Disorder and Schizophrenia. Neuropsychobiology, 2012, 65, 1-11.	0.9	53
45	Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. Journal of Psychiatry and Neuroscience, 2015, 40, 174-186.	1.4	53
46	The relationship between fibromyalgia and major depressive disorder: a comprehensive review. Current Medical Research and Opinion, 2008, 24, 2359-2371.	0.9	52
47	Paroxetine: safety and tolerability issues. Expert Opinion on Drug Safety, 2008, 7, 783-794.	1.0	51
48	Miniâ€Mental Status Examination as predictors of mortality in the elderly. Acta Psychiatrica Scandinavica, 2013, 127, 298-304.	2.2	50
49	Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam Medical Journal, 2016, 52, 159.	0.5	48
50	Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: A systematic review and meta-analysis. Journal of Psychiatric Research, 2015, 64, 88-98.	1.5	47
51	Adiposity parameters and cognitive function in the elderly: Application of "Jolly Fat―hypothesis to cognition. Archives of Gerontology and Geriatrics, 2009, 49, e133-e138.	1.4	45
52	Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. Journal of Psychopharmacology, 2010, 24, 1755-1763.	2.0	45
53	No difference in stroke knowledge between Korean adherents to traditional and western medicine – the AGE study: an epidemiological study. BMC Public Health, 2006, 6, 153.	1.2	44
54	Relationships between hand-grip strength, socioeconomic status, and depressive symptoms in community-dwelling older adults. Journal of Affective Disorders, 2019, 252, 263-270.	2.0	43

#	Article	IF	Citations
55	Antipsychotics and dopamine transporter gene polymorphisms in delirium patients. Psychiatry and Clinical Neurosciences, 2005, 59, 183-188.	1.0	42
56	Effects of CYP2D6 and CYP3A5 Genotypes on the Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Korean Schizophrenic Patients. Journal of Clinical Psychopharmacology, 2009, 29, 272-277.	0.7	42
57	Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Psychiatry Research, 2011, 189, 26-32.	1.7	42
58	VEGFR2 alteration in Alzheimer's disease. Scientific Reports, 2017, 7, 17713.	1.6	42
59	Milnacipran. Clinical Neuropharmacology, 2009, 32, 355-363.	0.2	39
60	Relationship of depression, chronic disease, self-rated health, and gender with health care utilization among community-living elderly. Journal of Affective Disorders, 2018, 241, 402-410.	2.0	39
61	No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatric Genetics, 2005, 15, 299-301.	0.6	38
62	Effects of Methylphenidate and Bupropion on DHEA-S and Cortisol Plasma Levels in Attention-deficit Hyperactivity Disorder. Child Psychiatry and Human Development, 2008, 39, 201-209.	1.1	37
63	Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis. Journal of Psychiatric Research, 2017, 84, 292-300.	1.5	37
64	Curcumin as a putative antidepressant. Expert Review of Neurotherapeutics, 2015, 15, 269-280.	1.4	36
65	Study design and methods of the Ansan Geriatric Study (AGE study). BMC Neurology, 2009, 9, 10.	0.8	35
66	Plasma Carbonic Anhydrase II protein is Elevated in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 21, 939-945.	1.2	35
67	A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. Clinical Psychopharmacology and Neuroscience, 2018, 16, 469-480.	0.9	35
68	Vilazodone for the Treatment of Depression: An Update. Chonnam Medical Journal, 2016, 52, 91.	0.5	34
69	Tinnitus, depression, and suicidal ideation in adults: A nationally representative general population sample. Journal of Psychiatric Research, 2018, 98, 124-132.	1.5	34
70	Altered expression of Notch1 in Alzheimer's disease. PLoS ONE, 2019, 14, e0224941.	1.1	34
71	Normative data and psychometric properties of the Patient Health Questionnaire-9 in a nationally representative Korean population. BMC Psychiatry, 2020, 20, 194.	1.1	33
72	Comparative efficacy and acceptability of pharmacological interventions for the treatment and prevention of delirium: A systematic review and network meta-analysis. Journal of Psychiatric Research, 2020, 125, 164-176.	1.5	33

#	Article	IF	CITATIONS
73	Psychiatric Symptoms Reported by International Peacekeeping Personnel in the Western Sahara Desert. Journal of Nervous and Mental Disease, 2001, 189, 858-860.	0.5	33
74	Bright light therapy as an adjunctive treatment with risperidone in patients with delirium: a randomized, open, parallel group study. General Hospital Psychiatry, 2012, 34, 546-551.	1.2	31
75	Case–control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 199-205.	1.8	31
76	A review of current evidence for vilazodone in major depressive disorder. International Journal of Psychiatry in Clinical Practice, 2013, 17, 160-169.	1.2	31
77	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 305-311.	1.8	30
78	Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study. Journal of Psychiatric Research, 2015, 66-67, 84-94.	1.5	30
79	Does Neurotropin-3 Have a Therapeutic Implication in Major Depression?. International Journal of Neuroscience, 2008, 118, 1515-1522.	0.8	28
80	Manganese superoxide dismutase gene Ala–9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1844-1847.	2.5	28
81	Usefulness of the Patient Health Questionnaire-9 for Korean Medical Students. Academic Psychiatry, 2014, 38, 661-667.	0.4	28
82	Assessing reporting quality of randomized controlled trial abstracts in psychiatry: Adherence to CONSORT for abstracts: A systematic review. PLoS ONE, 2017, 12, e0187807.	1.1	28
83	Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1219-1223.	2.5	27
84	The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder. Journal of Psychiatric Research, 2014, 56, 72-81.	1.5	27
85	Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action. Psychiatry Investigation, 2015, 12, 155.	0.7	26
86	Emotional labor and depressive mood in service and sales workers: Interactions with gender and job autonomy. Psychiatry Research, 2018, 267, 490-498.	1.7	25
87	Validation of the Korean version of the Generalized Anxiety Disorder 7 selfâ€rating Scale. Asia-Pacific Psychiatry, 2020, , e12421.	1.2	25
88	Alexithymia and low cooperativeness are associated with suicide attempts in male military personnel with adjustment disorder: A case–control study. Psychiatry Research, 2013, 205, 220-226.	1.7	24
89	Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. BMC Psychiatry, 2016, 16, 106.	1.1	24
90	Long-term treatment with long-acting risperidone in Korean patients with schizophrenia. Human Psychopharmacology, 2006, 21, 399-407.	0.7	23

#	Article	IF	CITATIONS
91	No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1545-1548.	2.5	23
92	Case–control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder. Psychiatry Research, 2012, 198, 39-46.	1.7	23
93	Asenapine, Blonanserin, Iloperidone, Lurasidone, and Sertindole. Clinical Neuropharmacology, 2013, 36, 223-238.	0.2	23
94	Genes Involved in Neurodevelopment, Neuroplasticity, and Bipolar Disorder: CACNA1C, CHRNA1, and MAPK1. Neuropsychobiology, 2016, 74, 159-168.	0.9	23
95	Standardization of the Korean Version of the Posttraumatic Embitterment Disorder Self-Rating Scale. Psychiatry Investigation, 2012, 9, 368.	0.7	23
96	Case-control association study of 36 single-nucleotide polymorphisms within 10 candidate genes for major depression and bipolar disorder. Psychiatry Research, 2013, 209, 121-123.	1.7	22
97	Psychometric Properties of the Patient Health Questionnaire–15 (PHQ–15) for Measuring the Somatic Symptoms of Psychiatric Outpatients. Psychosomatics, 2009, 50, 580-585.	2.5	21
98	Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. International Clinical Psychopharmacology, 2009, 24, 29-33.	0.9	21
99	Influence of the number and severity of somatic symptoms on the severity of depression and suicidality in community-dwelling elders. Asia-Pacific Psychiatry, 2014, 6, 274-283.	1.2	21
100	CACNA1C gene and schizophrenia. Psychiatric Genetics, 2015, 25, 163-167.	0.6	21
101	Plasma ATG5 is increased in Alzheimer's disease. Scientific Reports, 2019, 9, 4741.	1.6	21
102	Carotid intimaâ€media thickness in Parkinson's disease. Movement Disorders, 2007, 22, 2446-2449.	2.2	20
103	Experiences and barriers to implementation of clinical practice guideline for depression in Korea. BMC Psychiatry, 2013, 13, 150.	1.1	20
104	Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: A multi-center, naturalistic study. Journal of Psychiatric Research, 2014, 49, 75-82.	1.5	20
105	Perspectives on the Happiness of Community-Dwelling Elderly in Korea. Psychiatry Investigation, 2016, 13, 50.	0.7	20
106	Distinguishing Quantitative Electroencephalogram Findings between Adjustment Disorder and Major Depressive Disorder. Psychiatry Investigation, 2013, 10, 62.	0.7	20
107	G-Protein \hat{l}^2 (sub>3 (sub> Subunit C825T Polymorphism Tends to Be Associated with Seasonal Variation in Young Male College Students. Neuropsychobiology, 2005, 52, 135-139.	0.9	19
108	Thyroid hormones affect recovery from depression during antidepressant treatment. Psychiatry and Clinical Neurosciences, 2009, 63, 305-313.	1.0	19

#	Article	IF	CITATIONS
109	Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression. International Journal of Psychiatry in Clinical Practice, 2014, 18, 97-102.	1.2	19
110	Suicidal Ideation Among Korean Elderly: Risk Factors and Population Attributable Fractions. Psychiatry (New York), 2016, 79, 262-281.	0.3	19
111	Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. International Clinical Psychopharmacology, 2017, 32, 235-248.	0.9	19
112	Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2017, 37, 46-53.	0.7	19
113	Val158Met Polymorphism in the Catechol- <i>O</i> -Methyltransferase (<i>COMT)</i> Gene Is Not Associated with Tardive Dyskinesia in Schizophrenia. Neuropsychobiology, 2008, 57, 22-25.	0.9	18
114	Evidence for the Benefits of Nonantipsychotic Pharmacological Augmentation in the Treatment of Depression. CNS Drugs, 2013, 27, 21-27.	2.7	18
115	Metabolic Syndrome and Early Carotid Atherosclerosis in the Elderly. Journal of Atherosclerosis and Thrombosis, 2014, 21, 435-444.	0.9	18
116	Fibromyalgia diagnosis: a review of the past, present and future. Expert Review of Neurotherapeutics, 2015, 15, 667-679.	1.4	18
117	Investigational dopamine antagonists for the treatment of schizophrenia. Expert Opinion on Investigational Drugs, 2017, 26, 687-698.	1.9	18
118	A Normative Study of Lexical Verbal Fluency in an Educationally-Diverse Elderly Population. Psychiatry Investigation, 2013, 10, 346.	0.7	18
119	Interactive influences of demographics on the Mini-Mental State Examination (MMSE) and the demographics-adjusted norms for MMSE in elderly Koreans. International Psychogeriatrics, 2012, 24, 642-650.	0.6	17
120	Atypical antipsychotics as a possible treatment option for irritable bowel syndrome. Expert Opinion on Investigational Drugs, 2013, 22, 565-572.	1.9	16
121	Do We Need to Consider Ethno-cultural Variation in the Use of Atypical Antipsychotics for Asian Patients with Major Depressive Disorder?. CNS Drugs, 2013, 27, 47-51.	2.7	16
122	Increased Carotid Intima-Media Thickness and Plasma Homocysteine Levels Predict Cardiovascular and All-Cause Death: A Population-Based Cohort Study. European Neurology, 2013, 70, 1-5.	0.6	16
123	Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice. Chonnam Medical Journal, 2015, 51, 66.	0.5	16
124	Depression and Cognitive Function in Mild Cognitive Impairment: A 1-Year Follow-Up Study. Journal of Geriatric Psychiatry and Neurology, 2017, 30, 280-288.	1.2	16
125	Efficacy of antidepressants: bias in randomized clinical trials and related issues. Expert Review of Clinical Pharmacology, 2018, 11, 15-25.	1.3	16
126	Long working hours and depressive symptoms: moderation by gender, income, and job status. Journal of Affective Disorders, 2021, 286, 99-107.	2.0	16

#	Article	IF	Citations
127	Available therapies and current management of fibromyalgia: Focusing on pharmacological agents. Drugs of Today, 2011, 47, 539.	0.7	16
128	Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients. International Clinical Psychopharmacology, 2012, 27, 177-183.	0.9	15
129	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia. Neuroscience Letters, 2012, 506, 170-174.	1.0	15
130	Diagnosis and treatment of dementia in primary care. Journal of the Korean Medical Association, 2013, 56, 1104.	0.1	15
131	Precision medicine for psychopharmacology: a general introduction. Expert Review of Neurotherapeutics, 2016, 16, 831-839.	1.4	15
132	Characteristics of neurocognitive functions in mild cognitive impairment with depression. International Psychogeriatrics, 2016, 28, 1181-1190.	0.6	15
133	The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder. Advances in Therapy, 2017, 34, 713-724.	1.3	15
134	Measurement-based Treatment of Residual Symptoms Using Clinically Useful Depression Outcome Scale: Korean Validation Study. Clinical Psychopharmacology and Neuroscience, 2017, 15, 28-34.	0.9	15
135	Increased plasma complement factor H is associated with geriatric depression. International Psychogeriatrics, 2019, 31, 101-108.	0.6	15
136	Standardization of the Korean Version of the Patient Health Questionnaire-4 (PHQ-4). Clinical Psychopharmacology and Neuroscience, 2021, 19, 104-111.	0.9	15
137	Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample. Advances in Therapy, 2018, 35, 1656-1670.	1.3	14
138	Cerebral amyloid accumulation is associated with distinct structural and functional alterations in the brain of depressed elders with mild cognitive impairment. Journal of Affective Disorders, 2021, 281, 459-466.	2.0	14
139	Screening for Normal Cognition, Mild Cognitive Impairment, and Dementia with the Korean Dementia Screening Questionnaire. Psychiatry Investigation, 2018, 15, 384-389.	0.7	14
140	Depression, suicide, and Korean society. Journal of the Korean Medical Association, 2011, 54, 358.	0.1	13
141	Uptake of Web-Based Clinical Resources from the MacArthur Initiative on Depression and Primary Care. Community Mental Health Journal, 2013, 49, 166-171.	1.1	13
142	Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition. Journal of Korean Medical Science, 2014, 29, 468.	1.1	13
143	Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder. Psychiatry Investigation, $2014,11,481.$	0.7	13
144	Possible association between G-protein \hat{l}^2 3 subunit C825T polymorphism and antipsychotic-induced restless legs syndrome in schizophrenia. Acta Neuropsychiatrica, 2007, 19, 351-356.	1.0	12

#	Article	IF	CITATIONS
145	Delirium: Underrecognized and undertreated. Current Treatment Options in Neurology, 2008, 10, 386-395.	0.7	12
146	Methylphenidate Extended Release (OROS MPH) for the Treatment of Antidepressant-Related Sexual Dysfunction in Patients With Treatment-Resistant Depression. Clinical Neuropharmacology, 2009, 32, 85-88.	0.2	12
147	Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. Expert Review of Neurotherapeutics, 2011, 11, 1541-1552.	1.4	12
148	Paliperidone-associated atypical neuroleptic malignant syndrome: A case report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 650-651.	2.5	12
149	Management of Chronic Depressive Patients with Residual Symptoms. CNS Drugs, 2013, 27, 53-57.	2.7	12
150	Criticisms of drugs in early development for the treatment of depression: what can be improved?. Expert Opinion on Investigational Drugs, 2015, 24, 445-453.	1.9	12
151	Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression. Journal of Affective Disorders, 2019, 249, 410-417.	2.0	12
152	Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease. Archives of Gerontology and Geriatrics, 2020, 87, 103995.	1.4	12
153	Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for <i>CACNA1C, CHRNA7</i> and <i>MAPK1</i> . Clinical Psychopharmacology and Neuroscience, 2019, 17, 364-368.	0.9	12
154	The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study. Clinical Psychopharmacology and Neuroscience, 2019, 17, 495-502.	0.9	12
155	Association between work-family conflict and depressive symptoms in female workers: An exploration of potential moderators. Journal of Psychiatric Research, 2022, 151, 113-121.	1.5	12
156	History of early abuse as a predictor of treatment response in patients with fibromyalgia: A post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. World Journal of Biological Psychiatry, 2009, 10, 435-441.	1.3	11
157	Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder. International Clinical Psychopharmacology, 2013, 28, 322-329.	0.9	11
158	Posttraumatic Growth and Resilience: Assessment and Clinical Implications. Journal of Korean Neuropsychiatric Association, 2015, 54, 32.	0.2	11
159	The Influence of AHI1 Variants on the Diagnosis and Treatment Outcome in Schizophrenia. International Journal of Molecular Sciences, 2015, 16, 2517-2529.	1.8	11
160	PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study. Neuropsychobiology, 2016, 73, 160-168.	0.9	11
161	Intimate partner violence and incidence of depression in married women: A longitudinal study of a nationally representative sample. Journal of Affective Disorders, 2019, 245, 305-311.	2.0	11
162	Can botulinum toxin improve mood in depressed patients?. Expert Review of Neurotherapeutics, 2012, 12, 1049-1051.	1.4	10

#	Article	IF	Citations
163	Temperament and Character of Young Male Conscripts With Adjustment Disorder. Journal of Nervous and Mental Disease, 2012, 200, 973-977.	0.5	10
164	Plasma SUMO1 Protein is Elevated inÂAlzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 639-643.	1.2	10
165	Association between brain amyloid accumulation and neuropsychological characteristics in elders with depression and mild cognitive impairment. International Journal of Geriatric Psychiatry, 2019, 34, 1907-1915.	1.3	10
166	Association of metabolic syndrome and its components with suicidal ideation and depression in adults: A nationally representative sample of the Korean population. Journal of Affective Disorders, 2019, 249, 319-326.	2.0	10
167	Association between high-sensitivity C-reactive protein levels and depression: Moderation by age, sex, obesity, and aerobic physical activity. Journal of Affective Disorders, 2021, 291, 375-383.	2.0	10
168	A Korean validation study of the Clinically Useful Anxiety Outcome Scale: Comorbidity and differentiation of anxiety and depressive disorders. PLoS ONE, 2017, 12, e0179247.	1.1	10
169	Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. Current Opinion in Investigational Drugs, 2009, 10, 75-90.	2.3	10
170	Attitudes of patients and family members towards implantable psychiatric medication. Schizophrenia Research, 2008, 105, 279-286.	1.1	9
171	Paroxetine mesylate: comparable to paroxetine hydrochloride?. Expert Opinion on Pharmacotherapy, 2010, 11, 185-193.	0.9	9
172	Combination Treatment With Aripiprazole and Valproic Acid for Acute Mania. Clinical Neuropharmacology, 2012, 35, 97-102.	0.2	9
173	Possible influence of CREB1, CREBBP and CREM variants on diagnosis and treatment outcome in patients with schizophrenia. Neuroscience Letters, 2012, 508, 37-41.	1.0	9
174	Characteristics of Type D personality in Korean adolescents. European Child and Adolescent Psychiatry, 2012, 21, 699-706.	2.8	9
175	Do Somatic Symptoms Predict the Severity of Depression? A Validation Study of the Korean Version of the Depression and Somatic Symptoms Scale. Journal of Korean Medical Science, 2016, 31, 2002.	1.1	9
176	A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises. Psychiatry Investigation, 2014, 11, 371.	0.7	9
177	Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clinical Psychopharmacology and Neuroscience, 2020. 18. 153-158.	0.9	9
178	Impact of the Coronavirus Disease Pandemic on Mental Health among Local Residents in Korea: a Cross Sectional Study. Journal of Korean Medical Science, 2021, 36, e322.	1.1	9
179	DRD2/ANKK1 Taql A polymorphism affects corticostriatal activity in response to negative affective facial stimuli. Behavioural Brain Research, 2011, 223, 36-41.	1.2	8
180	Do we need more than one antidepressant for patients with major depressive disorder?. Expert Review of Neurotherapeutics, 2011, 11, 1561-1564.	1.4	8

#	Article	IF	Citations
181	Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial. Acta Neuropsychiatrica, 2011, 23, 179-183.	1.0	8
182	Case–control association study of GRIA1, GRIA2 and GRIA4 polymorphisms in bipolar disorder. International Journal of Psychiatry in Clinical Practice, 2012, 16, 18-26.	1.2	8
183	Investigation of Epistasis Between <i>DAOA</i> and <i>5HTR1A</i> Variants on Clinical Outcomes in Patients with Schizophrenia. Genetic Testing and Molecular Biomarkers, 2013, 17, 504-507.	0.3	8
184	Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection. Neuropsychiatric Disease and Treatment, 2014, 10, 1605.	1.0	8
185	Aripiprazole augmentation for major depressive disorder. International Clinical Psychopharmacology, 2014, 29, 116-119.	0.9	8
186	Five potential therapeutic agents as antidepressants: a brief review and future directions. Expert Review of Neurotherapeutics, 2015, 15, 1015-1029.	1.4	8
187	Effect of physical activity on suicidal ideation differs by gender and activity level. Journal of Affective Disorders, 2019, 257, 116-122.	2.0	8
188	Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 901-910.	1.8	8
189	Elevated Cerebrospinal Fluid and Plasma N-Cadherin in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2020, 79, 484-492.	0.9	8
190	History of Depressive and Anxiety Disorders and Paroxetine Response in Patients With Irritable Bowel Syndrome. Primary Care Companion To the Journal of Clinical Psychiatry, 2008, 10, 368-375.	0.6	8
191	Paliperidone. Clinical Drug Investigation, 2012, 32, 497-512.	1.1	8
192	Gender discrimination in workplace and depressive symptoms in female employees in South Korea. Journal of Affective Disorders, 2022, 306, 269-275.	2.0	8
193	Borna disease virus and deficit schizophrenia. Acta Neuropsychiatrica, 2003, 15, 262-265.	1.0	7
194	Treatment in risperidone-induced amenorrhoea. International Journal of Psychiatry in Clinical Practice, 2005, 9, 29-34.	1.2	7
195	Delirium: Where do we stand?. Current Psychiatry Reports, 2008, 10, 240-248.	2.1	7
196	Mental health economics, health service provision, and the practice of geriatric psychiatry. Current Opinion in Psychiatry, 2008, 21, 546-550.	3.1	7
197	Cholinesterase Inhibitors for Alzheimer Disease: Do They Provide More Than Symptomatic Benefits?. American Journal of Geriatric Psychiatry, 2011, 19, 266-273.	0.6	7
198	Zonisamide produces weight loss in psychotropic drug-treated psychiatric outpatients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1918-1921.	2.5	7

#	Article	IF	Citations
199	Association of sedative–hypnotic medications with suicidality. Expert Review of Neurotherapeutics, 2011, 11, 345-349.	1.4	7
200	Investigation of possible epistatic interactions between <i>GRIA2</i> and <i>GRIA4</i> variants on clinical outcomes in patients with major depressive disorder. Journal of International Medical Research, 2013, 41, 809-815.	0.4	7
201	The impact of 3D and 2D TV watching on neurophysiological responses and cognitive functioning in adults. European Journal of Public Health, 2015, 25, 1047-1052.	0.1	7
202	<p>Definition and Identification of Patients with Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2929-2941.	1.0	7
203	Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?. Clinical Psychopharmacology and Neuroscience, 2021, 19, 434-448.	0.9	7
204	Lack of association between antisperm antibodies and language dysfunction in Alzheimer's disease. Archives of Gerontology and Geriatrics, 2010, 50, 338-340.	1.4	6
205	Low Levels of Plasma Agmatine in the Metabolic Syndrome. Metabolic Syndrome and Related Disorders, 2010, 8, 21-24.	0.5	6
206	Serum Homocysteine and Folate Levels are Associated With Late-life Dementia in a Korean Population. Osong Public Health and Research Perspectives, 2010, 1, 17-22.	0.7	6
207	Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia. Clinical Psychopharmacology and Neuroscience, 2021, 19, 600-609.	0.9	6
208	Awareness of putative risk factors for Alzheimer's disease among elderly Koreans. Acta Neuropsychiatrica, 2008, 20, 20-24.	1.0	5
209	Duloxetine: An emerging evidence for fibromyalgia. Biomedicine and Pharmacotherapy, 2009, 63, 69-71.	2.5	5
210	DAOA Variants on Diagnosis and Response to Treatment in Patients with Major Depressive Disorder and Bipolar Disorder. Journal of International Medical Research, 2012, 40, 258-265.	0.4	5
211	Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role. Journal of Molecular Neuroscience, 2018, 64, 273-286.	1.1	5
212	How to approach to suicide prevention. Journal of the Korean Medical Association, 2019, 62, 79.	0.1	5
213	<p>Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2943-2959.	1.0	5
214	Comorbid Zolpidem Dependence and Over-the-Counter Compound Analgesic Abuse. Clinical Psychopharmacology and Neuroscience, 2019, 17, 323-325.	0.9	5
215	<i>ZNF804A</i> Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders. Clinical Psychopharmacology and Neuroscience, 2020, 18, 231-240.	0.9	5
216	Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study. Psychiatry Investigation, 2022, 19, 268-280.	0.7	5

#	Article	IF	Citations
217	DAOAvariants and schizophrenia: Influence on diagnosis and treatment outcomes. International Journal of Psychiatry in Clinical Practice, 2011, 15, 303-310.	1.2	4
218	Distressed personality without a partner enhances the risk of depression in patients with coronary heart disease. Asia-Pacific Psychiatry, 2013, 5, 284-292.	1.2	4
219	Oral scopolamine augmentation for major depression. Expert Review of Neurotherapeutics, 2013, 13, 19-21.	1.4	4
220	Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder. Clinical Psychopharmacology and Neuroscience, 2021, 19, 243-253.	0.9	4
221	Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics. Primary Care and Community Psychiatry, 2005, 10, 119-124.	0.4	4
222	Emotional Changes and Protective Factors of Emotional Workers in the Public and Private Sector. Psychiatry Investigation, 2020, 17, 645-653.	0.7	4
223	Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (I): Initial Choice of Antidepressant Treatment. Journal of Korean Neuropsychiatric Association, 2013, 52, 253.	0.2	4
224	Altered TIMP-3 Levels in the Cerebrospinal Fluid and Plasma of Patients with Alzheimer's Disease. Journal of Personalized Medicine, 2022, 12, 827.	1.1	4
225	Dilemma for enhancing psychiatrists' adherence to guideline (evidence)-based practice. Expert Review of Neurotherapeutics, 2013, 13, 751-754.	1.4	3
226	Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. Advances in Therapy, 2017, 34, 1482-1497.	1.3	3
227	Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. Journal of Molecular Neuroscience, 2018, 64, 62-74.	1.1	3
228	No borna disease virus-specific RNA detected in blood of race horses and jockeys. Acta Neuropsychiatrica, 2006, 18, 177-180.	1.0	2
229	Quetiapine augmentation for depression. International Clinical Psychopharmacology, 2015, 30, 54-58.	0.9	2
230	Sickness absence indicating depressive symptoms of working population in South Korea. Journal of Affective Disorders, 2018, 227, 443-449.	2.0	2
231	Possible Modulatory Role of ARC Gene Variants in Mood Disorders. Clinical Psychopharmacology and Neuroscience, 2021, 19, 46-52.	0.9	2
232	Changes in Brain Electrical Activity According to Post-traumatic Stress Symptoms in Survivors of the Sewol Ferry Disaster: A 1-year Longitudinal Study. Clinical Psychopharmacology and Neuroscience, 2021, 19, 537-544.	0.9	2
233	Brain amyloid accumulation possibly exacerbates concurrent mild cognitive impairment with subthreshold depression in older adults: A 1-year follow-up study. Journal of Affective Disorders, 2021, 295, 93-100.	2.0	2
234	Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (III): Dose Increment, Switching, Combination, and Augmentation Strategy in Antidepressant Therapy. Journal of Korean Neuropsychiatric Association, 2013, 52, 386.	0.2	2

#	Article	IF	CITATIONS
235	Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (II): Antidepressant Efficacy Compared with Placebo, Difference in Efficacy of Antidepressants, and Appropriate Time of Efficacy Judgment in Antidepressant Therapy. Journal of Korean Neuropsychiatric Association, 2013, 52, 372.	0.2	2
236	Epistatic Interactions between CREB and CREM Variants in Affective Disorder. Psychiatry Investigation, 2014, 11, 200.	0.7	2
237	Latency of auditory P300 correlates with self-control as measured by the Sixteen Personality Factor Questionnaire. Psychiatry and Clinical Neurosciences, 2005, 59, 418-424.	1.0	1
238	Attitudes on clinical research participation of community living elders in <scp>K</scp> orea. Asia-Pacific Psychiatry, 2012, 4, 168-173.	1.2	1
239	Second-to-fourth digit length ratio as a measure of harm avoidance. Personality and Individual Differences, 2016, 97, 30-34.	1.6	1
240	Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clinical Psychopharmacology and Neuroscience, 2021, 19, 233-242.	0.9	1
241	Importance of connectedness for the management of embitterment and loneliness in the era of COVID-19. Journal of the Korean Medical Association, 2021, 64, 394-399.	0.1	1
242	Reply to Comments on "Low Plasma BDNF is associated with Suicidal Behavior in Major Depressionâ€, Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 580-581.	2.5	0
243	Reply to Dr Ng's Comments on "A Randomized, Double-Blind, Placebo-Controlled Trial of Augmentation With An Extended Release Formulation of Methylphenidate in Outpatients With Treatment-Resistant Depression". Journal of Clinical Psychopharmacology, 2008, 28, 117-118.	0.7	0
244	Association of chronic divalproex sodium use and brain atrophy in Alzheimer's disease. Expert Review of Neurotherapeutics, 2012, 12, 155-158.	1.4	0
245	Will the Proteus sensor enhance adherence to aripiprazole or other antipsychotics?. Expert Review of Neurotherapeutics, 2017, 17, 319-321.	1.4	0
246	Impact of 2D and 3D display watching on EEG power spectra: A standardized low-resolution tomography (sLORETA) study. Signal Processing: Image Communication, 2021, 93, 116151.	1.8	0